Arif Arif A, Punnen Subin, Bleszynski Michael, Daniel R Owen, Yoshida Eric M
Department of Medicine, University of British Columbia, Vancouver BC, Canada.
Department of Surgery, University of British Columbia, Vancouver BC, Canada.
Hepatol Forum. 2024 Dec 24;6(2):69-71. doi: 10.14744/hf.2024.2024.0035. eCollection 2025.
Primary Biliary Cholangitis (PBC) is a chronic cholestatic liver disease that can lead to cirrhosis and the development of hepatocellular carcinoma. PBC is not known to be associated with hepatic angiosarcoma. Second-line treatments for PBC, including obeticholic acid, have had less than a decade of clinical use. We present a case of a patient with PBC treated with obeticholic acid who subsequently developed hepatic angiosarcoma. The patient is now on active surveillance following resection of the angiosarcoma. The development of this rare and aggressive cancer should prompt closer post-marketing surveillance for obeticholic acid.
原发性胆汁性胆管炎（PBC）是一种慢性胆汁淤积性肝病，可导致肝硬化和肝细胞癌的发生。目前尚不清楚PBC与肝血管肉瘤有关。PBC的二线治疗药物，包括奥贝胆酸，临床使用时间不到十年。我们报告一例接受奥贝胆酸治疗的PBC患者，该患者随后发生了肝血管肉瘤。该患者在切除血管肉瘤后目前正在接受积极监测。这种罕见且侵袭性癌症的发生应促使对奥贝胆酸进行更密切的上市后监测。
